Indian Hills Cherokee Section, United States
Indian Hills Cherokee Section, United States

Time filter

Source Type

Ho H.H.,Section of Ophthalmology | Savar A.,Section of Ophthalmology | Manning J.,University of Texas M. D. Anderson Cancer Center | Kasyan A.,University of Texas M. D. Anderson Cancer Center | Esmaeli B.,Section of Ophthalmology
Ophthalmic Plastic and Reconstructive Surgery | Year: 2010

Benign lymphoid hyperplasia is a disorder characterized by polyclonal lymphocytic infiltration of orbital tissues, predominantly with B-cells. Rituximab is a monoclonal antibody directed against CD20, a B-cell marker. Two patients with recurrent orbital masses involving the lacrimal glands were treated with rituximab. The diagnosis of benign lymphoid hyperplasia with predominance of CD20 + cells was confirmed in both cases based on a surgical biopsy. Both patients had been previously treated with standard therapies, including high-dose steroids, and one patient had failed external-beam radiation therapy. They both responded well to treatment with intravenous rituximab. Neither patient experienced any side effects associated with rituximab. © 2010 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.


PubMed | Section of Ophthalmology., Section of Hematology and Oncology. and University of Chicago
Type: Journal Article | Journal: Neuro-ophthalmology (Aeolus Press) | Year: 2016

A 56-year-old female with early-stage breast cancer, stage IA grade 1 endometrial cancer, and stage IC grade 1 ovarian cancer developed sudden-onset visual changes and right inferior visual field defect following anastrozole therapy. Examination revealed severe bilateral optic disc swelling and impaired visual acuity. Laboratory work-up was otherwise unremarkable. Anastrozole was discontinued and over the next month, patient had near-complete resolution of swelling in the right eye and improvement in the left eye. This is the only reported case of optic disc swelling following anastrozole therapy.


Williams M.D.,515 Holcombe Blvd. | Esmaeli B.,Section of Ophthalmology | Soheili A.,Section of Ophthalmology | Simantov R.,Curagen Corporation | And 3 more authors.
Melanoma Research | Year: 2010

Uveal melanoma is an aggressive disease without effective adjuvant therapy for metastases. Despite genomic differences between cutaneous and uveal melanomas, therapies based on shared biological factors could be effective against both tumor types. High expression of glycoprotein-NMB (GPNMB) in cutaneous melanomas led to the development of CDX-011 (glembatumumab vedotin), a fully human monoclonal antibody against the extracellular domain of GPNMB conjugated to the cytotoxic microtubule toxin monomethylauristatin E. Ongoing phase II trials suggest that CDX-011 has activity against advanced cutaneous melanomas. To determine the potential role of CDX-011 in uveal melanomas, we studied their GPNMB expression. Paraffin-embedded tissues from 22 uveal melanomas treated by enucleation from 2004-2007 at one institution were evaluated immunohistochemically for expression of GPNMB using biotinylated CDX-011 (unconjugated) antibody. Melanoma cells were evaluated for percentage and intensity of expression. Spectral imaging was used in one case with high melanin content. Clinical data were reviewed. Twelve women and 10 men with a median age of 58.7 years (range: 28-83 years) were included. Eighteen of 21 tumors evaluated immunohistochemically (85.7%) expressed GPNMB in 10-90% of tumor cells with variable intensity (5 tumors, 1+; 11, 2+; and 2, 3+). Eleven of 18 tumors (61.1%) expressed GPNMB in≥50% of cells. Spectral imaging showed diffuse CDX-011 (unconjugated) reactivity in the remaining case. Uveal melanoma, like cutaneous melanoma, commonly expresses GPNMB. Ongoing clinical trials of CDX-011 should be extended to patients with metastatic uveal melanoma to determine potential efficacy in this subset of patients with melanoma. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Cerase A.,Unit NINT Neuroimaging and Neurointervention | Leonini S.,Section of Radiology | Franceschini R.,Section of Ophthalmology | Grosso S.,University of Siena | Venturi C.,Unit NINT Neuroimaging and Neurointervention
Journal of Computer Assisted Tomography | Year: 2011

Our purpose was to increase the knowledge about subcortical low-intensity images on long repetition time by describing brain magnetic resonance images of a young boy after his first spontaneous seizure. Evident in the epileptogenic area were transient images of reversible subcortical low intensity on long-repetition time, T2*-weighted, and b = 0 s/mm diffusion, isointense signal on b = 1000 s/mm diffusion, and restricted diffusion. Most likely, mechanism was axonal flow disruption with iron accumulation and free radicals production induced during seizure. Copyright © 2011 by Lippincott Williams & Wilkins.


Abdolrahimzadeh S.,University of Rome La Sapienza | Scavella V.,University of Rome La Sapienza | Felli L.,Section of Ophthalmology | Cruciani F.,University of Rome La Sapienza | And 2 more authors.
BioMed Research International | Year: 2015

The phakomatoses have been traditionally defined as a group of hereditary diseases with variable expressivity characterized by multisystem tumors with possible malignant transformation. The Sturge-Weber syndrome, Klippel-Trenaunay syndrome, and the phakomatosis pigmentovascularis have the facial port-wine stain in common. Numerous pathophysiogenetic mechanisms have been suggested such as venous dysplasia of the emissary veins in the intracranial circulation, neural crest alterations leading to alterations of autonomic perivascular nerves, mutation of the GNAO gene in the Sturge-Weber syndrome, PIK3CA mutation in malformative/overgrowth syndromes such as the Klippel-Trenaunay syndrome, and the twin-spotting phenomenon in phakomatosis pigmentovascularis. Other features linked to the port-wine stain and typical to all of the three conditions are glaucoma and choroidal alterations. Glaucoma can be due to malformations of the anterior chamber or high episcleral venous pressure and in phakomatosis pigmentovascularis it can also be associated with angle hyperpigmentation. The choroid can be thickened in all diseases. Furthermore, choroidal melanocytosis in the phakomatosis pigmentovascularis can lead to malignant transformation. Although the multiple pathophysiological mechanisms still require clarification, similarities in ophthalmic manifestations make it reasonable to classify these diseases in an independent group. Copyright © 2015 Solmaz Abdolrahimzadeh et al.


PubMed | University of Rome La Sapienza and Section of Ophthalmology
Type: | Journal: BioMed research international | Year: 2015

The phakomatoses have been traditionally defined as a group of hereditary diseases with variable expressivity characterized by multisystem tumors with possible malignant transformation. The Sturge-Weber syndrome, Klippel-Trenaunay syndrome, and the phakomatosis pigmentovascularis have the facial port-wine stain in common. Numerous pathophysiogenetic mechanisms have been suggested such as venous dysplasia of the emissary veins in the intracranial circulation, neural crest alterations leading to alterations of autonomic perivascular nerves, mutation of the GNAO gene in the Sturge-Weber syndrome, PIK3CA mutation in malformative/overgrowth syndromes such as the Klippel-Trenaunay syndrome, and the twin-spotting phenomenon in phakomatosis pigmentovascularis. Other features linked to the port-wine stain and typical to all of the three conditions are glaucoma and choroidal alterations. Glaucoma can be due to malformations of the anterior chamber or high episcleral venous pressure and in phakomatosis pigmentovascularis it can also be associated with angle hyperpigmentation. The choroid can be thickened in all diseases. Furthermore, choroidal melanocytosis in the phakomatosis pigmentovascularis can lead to malignant transformation. Although the multiple pathophysiological mechanisms still require clarification, similarities in ophthalmic manifestations make it reasonable to classify these diseases in an independent group.

Loading Section of Ophthalmology collaborators
Loading Section of Ophthalmology collaborators